Xylo develops next-generation therapeutics focused on rewiring neural circuits to restore brain function. The company combines advanced neuroscience with computational drug discovery to create optimized treatments for neurological and psychiatric conditions. Their pipeline aims to enhance neuroplasticity to address critical gaps in current disorder treatments.
Funding
$13.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for mood disorders, addiction, and neurological diseases often fall short, leaving a significant unmet need for more effective and rapid-acting therapeutic options. Traditional psychiatric medications can have delayed effects or undesirable side effects, hindering patient recovery and quality of life.
Solution
Xylo is developing a new class of neuroplastogen therapeutics designed to rewire neural circuits and restore brain function for individuals suffering from neurological and psychiatric conditions. By combining advanced neuroscience with computational drug discovery, Xylo is creating optimized treatments that target specific receptors to promote neuroplasticity without the hallucinogenic effects associated with some psychedelic compounds. These small molecule therapeutics aim to address the underlying dysfunctions of brain disorders, offering the potential for long-term recovery rather than merely managing symptoms. Xylo's goal is to deliver transformative therapies that seamlessly integrate into existing healthcare systems, making these innovations accessible to a greater number of patients in need.
Target Audience
The primary target audience includes healthcare professionals, such as psychiatrists and neurologists, seeking innovative and effective treatment options for patients with mood disorders, addiction, and neurological diseases.
Features
- Novel small molecules designed to enhance neuroplasticity
- Targeted therapies focused on specific receptors relevant to psychiatric and neurological disorders
- Computational drug discovery approach for optimized treatment design
- Non-hallucinogenic compounds to improve patient access and tolerability
- Focus on rewiring neural circuits for long-term recovery